Recruiting
Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast Cancer
NCT06495515
- Conditions
- BRAEST CANCER, Cancer, Late Frontline, +1 more
- Locations
-
- Tianjin Medical University Cancer Institute and Hospital Tianjin, Tianjin Municipality, China